Evidence map›Paper›PMID 26142044›Full record

ArticleBMC infectious diseases2015

Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China.

Rong Wang, Xiao-Lei Guo, G Bea A Wisman, Ed Schuuring, Wen-Feng Wang, Zheng-Yu Zeng, Hong Zhu, Shang-Wei Wu

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 4 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 4 syntheses or guidelines pooled it, 181 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Rong WangDivision of Clinical Microbiology, School of Laboratory Medicine, Tianjin Medical University, Tianjin, China. wangrong825@126.com.
Xiao-Lei GuoDepartment of Microbiology, Kingmed Diagnostics, Guangzhou, China. labguoxiaolei@kingmed.com.cn.
G Bea A WismanDepartment of Gynecologic Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. g.b.a.wisman@umcg.nl.
Ed SchuuringDepartment of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. e.schuuring@umcg.nl.
Wen-Feng WangDepartment of Microbiology, Kingmed Diagnostics, Guangzhou, China. wangwenfeng840825@163.com.
Zheng-Yu ZengDepartment of Microbiology, Kingmed Diagnostics, Guangzhou, China. labzzy@kingmed.com.cn.
Hong ZhuDepartment of Epidemiology & Biostatistics, Tianjin Medical University, Tianjin, China. zhuhongepi@126.com.
Shang-Wei WuDivision of Clinical Microbiology, School of Laboratory Medicine, Tianjin Medical University, Tianjin, China. lab-wushangwei@kingmed.com.cn.
Kingmed Diagnostics · CNUniversity Medical Center Groningen · NLTianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType-specific high-risk HPV (hrHPV) infection is related to cervical carcinogenesis. The prevalence of hrHPV infection varies geographically, which might reflect the epidemiological characteristics of cervical cancer among different populations. To establish a foundation for HPV-based screening and vaccination programs in China, we investigated the most recent HPV prevalence and genotypic distributions in different female age groups and geographical regions in China.

methodsIn 2012, a total of 120,772 liquid-based cytological samples from women enrolled for population- or employee-based cervical screening in 37 Chinese cities were obtained by the Laboratory of Molecular Infectious Diseases of Guangzhou KingMed. A total of 111,131 samples were tested by Hybrid Capture II and the other 9,641 were genotyped using the Tellgenplex™ HPV DNA Assay.

resultsThe total positive rate for hrHPV was 21.07 %, which ranged from 18.42 % (Nanchang) to 31.94 % (Haikou) and varied by region. The regions of Nanchang, Changsha, Hangzhou, Chengdu, Fuzhou, Guangdong, and Guiyang could be considered the low prevalence regions. Age-specific prevalence showed a "two-peak" pattern, with the youngest age group (15-19 years) presenting the highest hrHPV infection rate (30.55 %), followed by a second peak for the 50-60-year-old group. Overall, the most prevalent genotypes were HPV16 (4.82 %) and HPV52 (4.52 %), followed by HPV58 (2.74 %). Two genotypes HPV6 (4.01 %) and HPV11 (2.29 %) were predominant in the low-risk HPV (lrHPV) type, while the mixed genotypes HPV16 + 52 and HPV52 + 58 were most common in women with multiple infections.

conclusionsThis study shows that HPV infection in China has increased to the level of an "HPV-heavy-burden" zone in certain regions, with prevalence varying significantly among different ages and regions. Data from this study represent the most current survey of the nationwide prevalence of HPV infection in China, and can serve as valuable reference to guide nationwide cervical cancer screening and HPV vaccination programs.

Indexed as

AdolescentAdultAge DistributionChinaCitiesDNA, ViralEarly Detection of CancerFemaleGenotypeHuman papillomavirus 11Human papillomavirus 16HumansMiddle AgedPapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesDNA, ViralPapillomavirus Vaccines

Identifiers

PMID26142044
PMCPMC4491249
OpenAlexW1583421205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.